BLACK WEEKSViaalid −15% · komplektid −10% · muu −5%koodigaTasuta tarne Saksamaal alates €200

See leht on tõlgitud automaatselt ja võib sisaldada vigu. Kas eesti keel on sinu emakeel? Ootame hea meelega sinu tagasisidet ja parandusi.Saada tagasisidet

The Peptide Desk The Peptide Desk
RAD-140 (Testolone), toote foto
SARMs

RAD-140 (Testolone)

SARMs

  • Saadetakse Saksamaalt

Tellimus

Ühiku hind - Black Weeksi ajal tasuta tarne Saksamaal alates 200 €
  • DHL koos jälgimisega
  • Diskreetne pakend

4.6 5-st Trustpilotis73 arvustust

Otsitud ka nimega: Testolon

Lühidalt

RAD-140 (Testolone) arvudes

Põhinäitajad meie leksikonist. Lohista punkti mööda kõverat, et näha, kui palju jääb pärast ühte annust arvutuslikult alles.

Täielik leksikoni artikkel

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~1.9 days

Half-life ~1.9 days
After 3.7 days: 25 %
Day 1, next dose69 %Day 1.949 %Day 3.725 %Day 5.612.4 %Day 9.33.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

44.7hours

measured in humans

Class
SARMnon-steroidal
Use
Oraldaily
Sizes
10 mg1 size in the shop

RAD-140 (Testolone) jaoks pole veel laborianalüüsi. Hääleta selle pooltLase ise testida, meie maksame pooleKõik laborianalüüsid

Teadmised

Kõik teemal RAD-140 (Testolone)

FAQ

Korduma kippuvad küsimused

Allikad iga vastuse juurde: leksikoni artikkel

Kas sul on veel küsimusi?

Kirjuta meile, meie meeskond aitab sind.

How does RAD-140 work?

According to ChEMBL RAD-140 binds to the androgen receptor with a Ki of 7 nM and activated it in muscle cells in the lab. Yu and colleagues found that it activates the receptor in breast cancer cells but not in prostate cancer cells. That is the tissue preference SARMs aim for.

Is RAD-140 approved?

No. On ClinicalTrials.gov there is a single study for RAD140, the completed phase 1 study in breast cancer (as of 26 October 2026). There are no studies in healthy people. Everything here is the state of research, not a recommendation.

What did the phase 1 study show?

22 heavily pretreated women with breast cancer took RAD-140 daily. SHBG fell in all 18 women measured, PSA rose in 16 of 20, a sign of action at the receptor. After 24 weeks 18.2 percent had a benefit, one woman a partial response. Liver values rose often.

What about the liver?

In the phase 1 study AST rose in 59.1 percent, ALT in 45.5 percent. In addition there are case reports. A 26-year-old had acute liver injury, his values normalised two months after stopping. A 24-year-old developed cholestatic liver injury after five weeks of use.

Are there reports on the heart?

Yes, as a case report: Padappayil and colleagues describe a young man with possible acute myocarditis after self-use of RAD-140 for bodybuilding. A case report does not prove a link, but it shows what to watch for.

Is muscle gain proven in humans?

No. The first description by Miller and colleagues shows anabolic effects in animal models. In humans there is only the phase 1 study in women with breast cancer, which did not measure muscle mass.

Võrdlused

Kuidas see võrdub

Seotud

Seotud tooted